A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Dec 10

PMID 34884767

Citations 8

Authors

Soudeh Ghafouri-Fard

Tahereh Azimi

Bashdar Mahmud Hussen

Mohammad Taheri

Reza Jalili Khoshnoud

Affiliations

Soon will be listed here.

Abstract

Myasthenia gravis (MG) is an autoimmune condition related to autoantibodies against certain proteins in the postsynaptic membranes in the neuromuscular junction. This disorder has a multifactorial inheritance. The connection between environmental and genetic factors can be established by epigenetic factors, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). XLOC_003810, SNHG16, IFNG-AS1, and MALAT-1 are among the lncRNAs with a possible role in the pathoetiology of MG. Moreover, miR-150-5p, miR-155, miR-146a-5p, miR-20b, miR-21-5p, miR-126, let-7a-5p, and let-7f-5p are among miRNAs whose roles in the pathogenesis of MG has been assessed. In the current review, we summarize the impact of miRNAs and lncRNAs in the development or progression of MG.

Citing Articles

Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.

Cabiati M, Federico G, Del Ry S Biomedicines. 2024; 12(9).

PMID: 39335501 PMC: 11429055. DOI: 10.3390/biomedicines12091988.

Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine.

Iacomino N, Tarasco M, Berni A, Ronchi J, Mantegazza R, Cavalcante P Cells. 2024; 13(18.

PMID: 39329732 PMC: 11430632. DOI: 10.3390/cells13181550.

The function of long non-coding RNA IFNG-AS1 in autoimmune diseases.

Zhao J, Gui Y, Wu W, Li X, Wang L, Wang H Hum Cell. 2024; 37(5):1325-1335.

PMID: 39004663 DOI: 10.1007/s13577-024-01103-9.

High indirect bilirubin levels as an independent predictor of postoperative myasthenic crisis: a single-center, retrospective study.

Sun C, Ruan Z, Zhang Y, Guo R, Li H, Wang T Front Neurol. 2024; 14:1336823.

PMID: 38283685 PMC: 10811789. DOI: 10.3389/fneur.2023.1336823.

MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis.

Sun J, Sun M, Li X, Xie Q, Zhang W, Wang M Exp Ther Med. 2024; 27(1):6.

PMID: 38223327 PMC: 10785013. DOI: 10.3892/etm.2023.12293.

References

Cron M, Payet C, Fayet O, Maillard S, Truffault F, Fadel E . Decreased expression of miR-29 family associated with autoimmune myasthenia gravis. J Neuroinflammation. 2020; 17(1):294. PMC: 7545844. DOI: 10.1186/s12974-020-01958-3. View

Hong Y, Liang X, Gilhus N . AChR antibodies show a complex interaction with human skeletal muscle cells in a transcriptomic study. Sci Rep. 2020; 10(1):11230. PMC: 7343820. DOI: 10.1038/s41598-020-68185-x. View

Sabre L, Maddison P, Sadalage G, Ambrose P, Punga A . Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. J Neuroimmunol. 2018; 321:164-170. DOI: 10.1016/j.jneuroim.2018.05.003. View

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A . Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016; 263(8):1473-94. PMC: 4971048. DOI: 10.1007/s00415-016-8045-z. View

Cao Y, Wang J, Zhang H, Tian Q, Chen L, Ning S . Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis. Biomed Res Int. 2015; 2015:724715. PMC: 4331476. DOI: 10.1155/2015/724715. View

Punga A, Andersson M, Alimohammadi M, Punga T . Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J Neurol Sci. 2015; 356(1-2):90-6. DOI: 10.1016/j.jns.2015.06.019. View

Cao Y, Lu X, Wang J, Zhang H, Liu Z, Xu S . Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. Int J Mol Med. 2017; 39(2):268-278. PMC: 5358695. DOI: 10.3892/ijmm.2017.2853. View

Luo M, Liu X, Meng H, Xu L, Li Y, Li Z . IFNA-AS1 regulates CD4 T cell activation in myasthenia gravis though HLA-DRB1. Clin Immunol. 2017; 183:121-131. DOI: 10.1016/j.clim.2017.08.008. View

Punga T, Le Panse R, Andersson M, Truffault F, Berrih-Aknin S, Punga A . Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol. 2014; 1(1):49-58. PMC: 4207504. DOI: 10.1002/acn3.24. View

10.

Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A . Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001; 7(3):365-8. DOI: 10.1038/85520. View

11.

Xu H, Bao Z, Liang D, Li M, Wei M, Ge X . Plasma exosomal miR-106a-5p expression in myasthenia gravis. Muscle Nerve. 2020; 61(3):401-407. DOI: 10.1002/mus.26785. View

12.

Sabre L, Guptill J, Russo M, Juel V, Massey J, Howard Jr J . Circulating microRNA plasma profile in MuSK+ myasthenia gravis. J Neuroimmunol. 2018; 325:87-91. PMC: 6240475. DOI: 10.1016/j.jneuroim.2018.10.003. View

13.

Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

14.

Lu H, Wang H, Sun P, Wang J, Li S, Xu T . MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells. Cytotechnology. 2021; 73(3):483-496. PMC: 8167029. DOI: 10.1007/s10616-021-00472-5. View

15.

Shi L, Liu T, Zhang M, Guo Y, Song C, Song D . miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice. Med Sci Monit. 2015; 21:1774-80. PMC: 4485652. DOI: 10.12659/MSM.893458. View

16.

Barzago C, Lum J, Cavalcante P, Srinivasan K, Faggiani E, Camera G . A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology. 2016; 221(11):1227-36. DOI: 10.1016/j.imbio.2016.06.012. View

17.

Punga T, Bartoccioni E, Lewandowska M, Damato V, Evoli A, Punga A . Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J Neuroimmunol. 2016; 292:21-6. DOI: 10.1016/j.jneuroim.2016.01.003. View

18.

Europa T, Nel M, Heckmann J . Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis. Orphanet J Rare Dis. 2020; 15(1):346. PMC: 7731744. DOI: 10.1186/s13023-020-01629-9. View

19.

Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z . Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int J Mol Sci. 2019; 20(22). PMC: 6888083. DOI: 10.3390/ijms20225573. View

20.

Zagoriti Z, Kambouris M, Patrinos G, Tzartos S, Poulas K . Recent advances in genetic predisposition of myasthenia gravis. Biomed Res Int. 2013; 2013:404053. PMC: 3835684. DOI: 10.1155/2013/404053. View